Kraig Biocraft Laboratories (KBLB) Equity Average (2011 - 2025)

Kraig Biocraft Laboratories has disclosed Equity Average across 13 years of filings, most recently posting -$8.0 million for Q4 2025.

• Equity Average for Q4 2025 came in at -$8.0 million, down 2.89% year-over-year; the trailing twelve-month figure through Dec 2025 was -$8.0 million (down 2.89% YoY), and the FY2025 annual result was -$8.1 million, down 16.54% from the prior year.
• Equity Average came in at -$8.0 million for Q4 2025 at Kraig Biocraft Laboratories, up from -$8.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of -$3.7 million in Q4 2022 to a low of -$8.5 million in Q2 2025.
• The 5-year median for Equity Average is -$5.8 million (2021), against an average of -$5.9 million.
• Across the five-year window, Equity Average surged 34.74% in 2022 and slumped 58.08% in 2024, its largest moves.
• Kraig Biocraft Laboratories' Equity Average stood at -$5.6 million in 2021, then soared by 34.74% to -$3.7 million in 2022, then slumped by 46.49% to -$5.4 million in 2023, then tumbled by 44.84% to -$7.8 million in 2024, then slipped by 2.89% to -$8.0 million in 2025.
• The last three Equity Average figures came in at -$8.0 million (Q4 2025), -$8.2 million (Q3 2025), and -$8.5 million (Q2 2025), per Business Quant data.